Highlights
• Sigma Healthcare rose 0.93% to $2.715 on 4 September 2026
• Pro-forma Revenue increased 14.9% in H1 FY2026 following the Chemist Warehouse acquisition
• EBIT rose 18.7% to A$582.9 million in the half-year result
• Total operating expenses increased 9.8% to A$451.8 million
Sigma Healthcare Ltd (ASX:SIG) edged higher by 0.93% to $2.715 on 4 September 2026, continuing to attract investor attention as the market digests its transformative integration of Chemist Warehouse Group and the operational Leverage it is generating from the enlarged combined business.
About the Company
Sigma Healthcare is one of Australia's leading pharmaceutical wholesalers and distributors. The company underwent a landmark transformation with the Acquisition of Chemist Warehouse Group, creating a vertically integrated healthcare and retail pharmacy powerhouse. Sigma supplies prescription and over-the-counter medicines, healthcare products and services to community pharmacies across the country, while Chemist Warehouse operates one of Australia's largest pharmacy retail networks.
Key Developments
Sigma Healthcare's FY2026 half-year results covered the six months ended 31 December 2025 following its acquisition of Chemist Warehouse Group. Pro-forma revenue increased 14.9%, while EBIT rose 18.7% to A$582.9 million. Total operating expenses increased 9.8% to A$451.8 million, with the company highlighting supply-chain consolidation and operating leverage.
Key Catalysts to Watch
• Full-year FY2026 result and any updated guidance for FY2027
• Progress on supply-chain consolidation synergies from the Chemist Warehouse merger
• Growth in pharmacy retail volumes and dispensing revenue
• Potential for further Margin expansion as integration matures
Risks
• Integration execution risk from the large-scale Chemist Warehouse merger
• Regulatory scrutiny of pharmacy distribution practices
• Competition from independent pharmacy groups and rival distributors
• Rising cost pressures in the pharmacy Supply chain
Conclusion
Sigma Healthcare's half-year results paint a compelling picture of a company successfully leveraging its Chemist Warehouse acquisition to drive meaningful revenue and Earnings growth. With EBIT up nearly 19% and Operating Leverage clearly emerging, the story remains one of scale and synergies. The 0.93% gain on 4 September suggests continued market confidence. Investors will be watching the full-year result and the pace of supply-chain integration closely in the months ahead.






Please wait processing your request...